Splash

Investors

We are committed to delivering our strategy and creating value for our shareholders.
Splash
Investors
Latest Results

Latest Results

We’re pleased to announce our latest results.

Download Results

Latest News

Latest Events

August 29 2022Regulatory
Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the H.C. Wainwright 24 th Annual Global Investment Conference on Monday, September 12, 2022 at 2:00 PM

August 24 2022Regulatory
Verona Pharma Strengthens Commercialization Leadership Team

LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, continues its preparation for commercialization with appointments of Matthew Casbon, Vice

August 19 2022Regulatory
Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China

LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, Nuance Pharma, has received clearance from the Center of

View all regulatory news
Splash

© Verona Pharma plc 2022. All rights reserved